After their inoculation into immunocompetent C57BL/6 mice, wild-type tumors were responsive to sorafenib treatment, whereas IFNGR1-deficient tumors failed to respond (Fig. 1e), suggesting that the integrity of IFNγ signaling in HCC cells is required for TKI response in vivo. This evidence concerns the gene IFNG and hepatocellular carcinoma.